Epidarex Capital has launched a new drug discovery initiative providing seed funding and hands-on support to nurture fledgling projects.

Alexandria Venture Investments has backed a series A round for Jasper Therapeutics, which is developing a conditioning agent for patients awaiting stem cell transplants.

Agilent Technologies contributed to a $50m round for the tissue-imaging technology developer, which has earmarked the funds for product development.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Existing backer Banco Sabadell Venture Capital contributed to a round that will help the stroke surgery device developer fund clinical studies.

Legend Capital returned as the RNA drug developer secured $28.8m in a round co-led by Panlin Capital and Trinity Innovation Fund.

Kooksoondang Brewery took part in a series B round for oncology antibody developer Hummingbird Bioscience as it prepares to move its lead assets into the clinic.

Building on translational science from Stanford, Jasper has secured funding to progress its Amgen-licensed conditioning agent for patients awaiting stem cell transplants.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The cancer drug developer emerged from stealth with $194m in funding, $85m of which was just closed in a round featuring returning investor Roche Venture Fund.